These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Improved preparation of leukocytes for chemiluminescent study of human phagocytic leukocyte-generated reactive oxygen species. Saniabadi AR; Nakano M J Biolumin Chemilumin; 1993; 8(4):207-13. PubMed ID: 8396845 [TBL] [Abstract][Full Text] [Related]
43. Introduction: timing of leukodepletion of blood products. Heaton A Semin Hematol; 1991 Jul; 28(3 Suppl 5):1-2. PubMed ID: 1925635 [No Abstract] [Full Text] [Related]
44. Improvement in isolation of human peripheral blood leukocyte subpopulations: application in diagnosing human cytomegalovirus infection in bone marrow transplant patients. Behzad-Behbahani A; Yaghobi R; Sabahi F; Rostaei MH; Alborzi A Exp Clin Transplant; 2005 Jun; 3(1):316-9. PubMed ID: 15989676 [TBL] [Abstract][Full Text] [Related]
45. [Present status of the use of fresh whole blood]. Fujii H Rinsho Byori; 1991 Mar; Suppl 88():402-9. PubMed ID: 1856991 [No Abstract] [Full Text] [Related]
46. Interpretation of atypical patterns encountered when using a flow cytometry-based method to detect residual leukocytes in leukoreduced red blood cell components. Janatpour K; Paglieroni TG; Schuller L; Foley K; Rizzardo T; Holland PV Cytometry; 2002 Oct; 50(5):254-60. PubMed ID: 12360575 [TBL] [Abstract][Full Text] [Related]
52. [Biological properties of cryopreserved leukocytes and their clinical application]. Agranenko VA; Faĭnshteĭn FE; Ermolovich SV; Khoroshko ND; Abezgauz NN Probl Gematol Pereliv Krovi; 1982 Apr; 27(4):6-10. PubMed ID: 6954458 [No Abstract] [Full Text] [Related]
53. Improved erythrocyte sedimentation and leucocyte recovery with Dextran T500. Antrum RM; Solomkin JS Med Lab Sci; 1986 Jan; 43(1):44-7. PubMed ID: 2421125 [No Abstract] [Full Text] [Related]
54. [Preparation of leukocyte poor blood. Comparison of 5 different methods]. Rasmussen NJ; Grunnet N Ugeskr Laeger; 1981 Nov; 143(45):2974-7. PubMed ID: 7330990 [No Abstract] [Full Text] [Related]
55. [The possibility of blood component therapy in Croatia (author's transl)]. Grgicević D; Bozović I; Pende B Lijec Vjesn; 1981; 103(2-3):119-22. PubMed ID: 7311696 [No Abstract] [Full Text] [Related]
56. Storage times of whole blood and of buffy coat determine leucocyte degradation in platelet concentrates. Karger R; Kretschmer V Vox Sang; 2005 Oct; 89(3):170; author reply 171. PubMed ID: 16146511 [No Abstract] [Full Text] [Related]
57. Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers. Seghatchian J Transfus Apher Sci; 2006 Feb; 34(1):125-30. PubMed ID: 16376152 [TBL] [Abstract][Full Text] [Related]
58. [Comparative characteristics of an erythrocyte suspension with different plasma-substitute solutions]. Poliakova LP; Agranenko VA; Suvorova IA; Golubeva VL; Borzova LV Probl Gematol Pereliv Krovi; 1980 Jan; 25(1):11-5. PubMed ID: 7367394 [No Abstract] [Full Text] [Related]
59. Rationale and strategy for utilization of available blood in transfusion practice--an overview. Khurana SK; Thergaonkar A; Dhupia JS; Verma SK; Talib VH Indian J Pathol Microbiol; 1996 Oct; 39(4):343-54. PubMed ID: 9009494 [No Abstract] [Full Text] [Related]